obesity

News

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.

News

Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.

News

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.

News

Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.

News

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.

News

Eli Lilly has used an Oscars ad to urge people not to use unapproved and untested weight-loss medicines in a swipe at the compounding sector.